Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02115


Purpose:

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)


Study summary:

This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.


Criteria:

Inclusion Criteria: - Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2. - Must have acceptable organ and marrow function per protocol parameters. - No clinically significant ventricular arrythmias or ischemia. Exclusion Criteria: - Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks.. - No previous radiation to >25% of total bone marrow. - No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation. - No primary brain tumors or active brain metastases. - No use of any investigational agents within 4 weeks. - No treatment with chronic immunosuppressants. - No uncontrolled, intercurrent illness.


NCT ID:

NCT00688116


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.